To help answer common vaccine questions, we consulted Dr. Stanley Perlman, a professor at the University of Iowa’s Carver ...
In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...
Goldman Sachs made significant rating changes across its U.S. biopharma coverage on Tuesday, upgrading the likes of Eli Lilly (LLY) and Johnson & Johnson (NYSE:JNJ) while downgrading Bristol Myers ...
Pfizer (NYSE:PFE) has entered a non exclusive licensing agreement with Novavax for access to its Matrix-M adjuvant technology. The company is also participating in the White House TrumpRx initiative, ...
PFE, has entered a global licensing agreement with Novavax to use Matrix-M adjuvant technology in the development of up to two infectious disease vaccines. The deal grants Pfizer non-exclusive ...
Pfizer PFE is set to report its fourth-quarter and full-year 2025 earnings on Feb. 3, before market open. The Zacks Consensus ...
Pfizer is exiting its HIV-focused joint venture, ViiV Healthcare, while reshaping its portfolio around other therapeutic ...
According to TipRanks.com, Haider is a 4-star analyst with an average return of 26.2% and a 87.5% success rate. Haider covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results